Roche Holding AG isn’t done making moves in the obesity market after last month’s agreement to buy Carmot Therapeutics Inc. for as much as $3.1 billion (CHF2.64 billion).
This content was published on
2 minutes
Bloomberg
The Swiss drugmaker said on Tuesday that it’s on the hunt for additional biotech partners to help it challenge weight-loss leaders Novo Nordisk A/S and Eli Lilly & Co. Roche is looking for new ways of adjusting metabolism that could ultimately be combined with treatments it’s gaining in the Carmot deal.
“This is opening up a whole new vista for us,” James Sabry, Roche’s head of partnering, said in an interview on the sidelines of the JPMorgan Healthcare Conference in San Francisco.
More
More
Roche declares war on obesity with billion-dollar takeover
This content was published on
Pharmaceutical company Roche is entering the fight against obesity with the $2.7 billion takeover of United States firm Carmot Therapeutics.
Carmot was one in a flurry of recent deals Roche has made to bolster its pipeline. The company is also interested in oncology, neurology and ophthalmology as well as cardiovascular medicine, Sabry said.
While many companies are trying to break into the hot weight-loss market, Sabry said Roche is one of only a handful of suitors with the size and global reach to run the large, costly trials necessary to bring new drugs to market. Marketing obesity medicines is also more complicated than other areas like cancer because drugmakers need to deal with primary-care doctors instead of a few specialised treatment centres, he said.
More
More
What lies ahead for Switzerland: the economic outlook for 2024
This content was published on
SWI swissinfo.ch journalists select the major developments that await the Swiss economy in 2024.
“When we’re trying to get a deal done, we find more competitors in oncology,” he said. “You’d think everyone must be competing with you for metabolism drugs, but it’s not that way.”
Roche was one of the first pharmaceutical companies to work on an experimental drug in the GLP-1 class, a category that includes Novo’s Wegovy and Lilly’s Zepbound. But it halted development more than a decade ago after patients dropped out of a study due to side effects such as nausea.
This content was published on
The Ethos Foundation recommends that shareholders vote against all compensation-related items at the Annual General Meeting on March 7.
Top Swiss firms close to reaching gender quota in boards
This content was published on
The proportion of women on the boards of directors of the fifty largest listed companies in Switzerland currently stands at 28%.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.